Research Advances in Multiple Myeloma with Chromosome 1q21 Amplification.
10.19746/j.cnki.issn.1009-2137.2022.02.056
- Author:
Chen WANG
1
;
Rong HU
2
Author Information
1. First Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, China.
2. First Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, China,E-mail: hur@sj-hospital.org.
- Publication Type:Review
- Keywords:
1q21;
karyotype;
multiple myeloma
- MeSH:
Chromosome Aberrations;
Chromosomes;
Chromosomes, Human, Pair 1/genetics*;
Hematopoietic Stem Cell Transplantation;
Humans;
Multiple Myeloma/drug therapy*;
Prognosis
- From:
Journal of Experimental Hematology
2022;30(2):649-652
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a kind of hematologic malignancy occurring in plasma cells. Cytogenetic technique plays an important role in risk stratification of MM. 1q21 amplification is one of the common chromosomal abnormalities in MM. Studies have shown that 1q21 amplification is associated with poor prognosis in MM patients. At present, with the development of new drugs, cellular immunotherapy, and improvement of hematopoietic stem cell transplantation technology, the remission depth and survival time of MM significantly increased. Rapid and accurate identification of high-risk patients and individualized treatment according to the patient's condition is the key to improve the therapeutic effect of MM. This article reviews the mechanism of 1q21 amplification in MM and the efficacy of new drugs in the treatment of MM with 1q21 chromosome amplification.
